Abrogation of functional p53 is responsible for malignant cell transformation and maintenance of human papilloma virus (HPV)-infected cancer cells. Restoration of p53 has, therefore, been regarded as an important strategy for molecular intervention of HPV-associated malignancies. Here we report that differential regulation of pro-and anti-p53 setups not only upregulates p53 transcription but also stabilizes and activates p53 protein to ensure p53-induced apoptosis in HPV-18-infected cervical cancer. Functional restoration of p53 can be achieved by nonsteroidal anti-inflammatory drug celecoxib via multiple molecular mechanisms: (i) inhibition of p53 degradation by suppressing viral oncoprotein E6 expression, (ii) promoting p53 transcription by downmodulating cycloxygenase-2 (Cox-2) and simultaneously retrieving p53 from Cox-2 association and (iii) activation of p53 via ataxia telangiectasia mutated-/p38 mitogen-activated protein kinase-mediated phosphorylations at serine-15/-46 residues. That restored p53 is functional has been confirmed by its ability of transactivating Bax and p53-upregulated modulator of apoptosis, which in turn switch on the apoptotic machinery in these cells. Studies undertaken in biopsy samples of cervical carcinoma further validated celecoxib effect. Our approaches involving gene manipulation and pharmacological interference finally highlight that celecoxib alters pro-and anti-p53 networks, not in isolation but in concert, to rejuvenate p53-dependent apoptotic program in HPV-infected cervical cancer cells.
Introduction
A functional p53-network is indispensable for the ability of p53 to suppress tumor formation as well as for mediating the cellular responses to many standard anti-cancer therapies (Choudhuri et al., 2005; Fuster et al., 2007; Lahiry et al., 2008; Adhikary et al., 2010; Chakraborty et al., 2010) . Tumor suppressor protein p53 when stimulated regulates the cellular localization and activity of key effectors involved in the apoptotic process (Lahiry et al., 2008) . However, in order to overcome the threats posed by a functional p53-network, tumor cells either activate an anti-p53 network to hamper p53 functions or else directly acquire p53 mutations, (Royds and Iacopetta 2006; Meulmeester and Jochemsen, 2008) thereby predicting a substantially worsened prognosis and treatment. The best example can be that of virally infected cervical cancers where despite the presence of wild-type p53 gene, a number of mechanisms co-operate to suppress the functional execution of a pro-p53-network (Kastan, 2007) .
Cervical cancer is the second most common cause of death from cancer among women worldwide and remains a major basis of mortality among women of reproductive age in developing countries. Strong epidemiologic and experimental evidence has linked infection with 'high-risk' human papillomaviruses (HPVs), , which infect the anogenital mucosa that ultimately, progress to the development of cervical carcinoma (Chakrabarti and Krishna, 2003) . The carcinogenic process is linked to activities of two fundamental viral oncogenes, E6 and E7. They exert pleotropic effects on the cell in which they are expressed, for example, E7 proteins control several key cell cycle control proteins, including pRb, resulting in unscheduled DNA replication (Mun˜oz et al., 2003) whereas E6 protein inactivates p53 by forming a stable bond with p53 and E6 associated protein (E6-AP) leading to ubiquitination-mediated degradation of p53 (Scheffner et al., 1993) . Thus, E6 counteracts the normal apoptotic and cell cycle arrest responses of HPV-positive cells escalating the abnormal growth stimulus, ultimately resulting in deregulated cell proliferation. Several reports have shown that E6 function is inevitable for the protection of cervical cancer cells from apoptosis and silencing this oncogene restores the dormant p53 functions (Zhao et al., 2010) . Therefore, E6, contributing effectively in anti-p53 network, represents one of the most promising therapeutic targets for the treatment of HPV-positive tumors and dysplasias.
Apart from E6, several studies have identified complex cross-talks between p53 and cyclooxygenase-2 (Cox-2), whereby p53 can either up or downregulate Cox-2, which in turn controls p53 transcriptional activity (de Moraes et al., 2007) . A recent report has shown that downregulating Cox-2 induced p53 levels in HCT-116 cells (Swamy et al., 2003) . Concurrently Corcoran et al. (2005) have demonstrated that Cox-2 interacts with p53 and interferes with p53-dependent transcription and apoptosis. It is clear that both p53 and Cox-2 are inducible proteins whose expression and activity are under tight regulatory controls and aberrations in the activities of both have been associated with tumorigenesis. For example, p53 is frequently inactivated in various cancers, while Cox-2 is overexpressed in a variety of malignancies suggesting the possibility of interplay between these two very important molecules. As Cox-2 negatively regulates p53, it is reasonable to suggest that the aberrant constitutive overexpression of Cox-2 noted in various malignancies could continue to negatively affect p53 function in tumors that harbor wild-type p53. Hence the chances of Cox-2 suppressing the p53-network in cervical cancer cells appears logical and therefore its inhibition might as well improve the clinical prognosis of cervical cancer patients more because Cox-2 contributes to most of the inflammatory processes during different stages of virally infiltrated cancers (Subbaramaiah and Dannenberg, 2007) .
With p53 at stake in cervical cancer cells, a novel therapeutic approach should therefore aim towards not only inducing p53 functions but also regulating the balance of pro-vs anti-p53 network. In our study, for the first time we have reported that celecoxib a nonsteroidal anti-inflammatory drug, suppresses the antip53-network to generate a pro-p53 environment thereby resulting in p53-dependent apoptosis in HPV-18-infected cervical cancer cells. Our study demonstrates that celecoxib stabilizes p53 by downregulating E6 transcription. Celecoxib also induces p53 transcription along with relieving p53 from the sequestered p53-Cox-2 complex by abrogating Cox-2 expression. Finally, celecoxib induces ataxia telangiectasia mutated (ATM)-/ p38 mitogen-activated protein kinase (MAPK)-mediated p53 phosphorylations at serine-15/-46 to activate p53-dependent transcription of Bax and p53 upregulated modulator of apoptosis (PUMA) resulting in apoptosis. In summary our work focuses on stabilization and functional maturation of p53 and its significance during celecoxib-mediated cervical cancer cell apoptosis. It therefore suggests that therapies designed to globally maneuver a functional pro-p53 network over an anti-p53-network could be successful in the management of virally infected cervical cancers.
Results
Celecoxib induces apoptosis in HPV-18-infected cervical cancer cells by regulating p53 stabilization and function The effect of celecoxib on the viability of wild-type p53-expressing HPV-infected cervical cancer cells was examined. Figure 1a depicted the dose-and timedependent effect of celecoxib on the viability of HeLa cells, indicating that celecoxib induced significant cell death at concentration starting from 15 mM on exposure for 24 h. As concentrations beyond 25 mM were simultaneously found to be toxic for normal lung fibroblast cells (Figure 1a) , further experiments were restricted to 25 mM of celecoxib. To assess whether reduction in cell number is due to increased apoptosis we analyzed the number of Annexin-V-positive cells by flow cytometry. Figure 1b shows significant increase in number of Annexin-V-positive cervical cancer cells (Figure 1b) , indicating apoptosis as the primary mode of cell death.
As in HeLa cells HPV-18 E6 is known to degrade p53, we hypothesized that celecoxib might be inducing apoptosis through p53 paralogue p63 or p73. However, celecoxib failed to change the status of both p63 and p73 in these cells (Figure 1c) . Interestingly, HeLa cells could overcome celecoxib-insult significantly when transfected with p53-short-interfering RNA (siRNA) (Figure 1c ). These results indicate the involvement of p53 in celecoxib-induced apoptosis in these cells. To understand the mechanism as to how the 'otherwise degraded' p53 is having such an important role we designed various experiments. Reverse transcriptase PCR and western blot analyses depicted that celecoxib significantly increased p53 expression at mRNA and protein levels ( Figure 1d ). Additionally, confocal imaging and western blot analysis of sub-cellular fractions strongly suggested that celecoxib induced translocation of p53 from cytosol to nucleus (Figure 1d ). In addition, mRNA levels of p53-transactivated Bax and PUMA were upregulated in the presence of this drug, (Figure 1e ; left panel) thereby confirming that nuclear p53 is functionally active. That functional p53 is inevitable for celecoxib-induced apoptosis was further confirmed when silencing p53 targets, Bax and PUMA, negated Hela cells apoptosis (Figure 1e ; right panel). These results demonstrating that celecoxib modulates p53 at both transcriptional as well as translational levels tempted us to delineate the complete mechanism underlying the functional restoration of p53 in these virally infected cervical cancer cells.
Abrogation of E6 is imperative to induce p53 stabilization but not sufficient to restore p53 function during celecoxib-mediated apoptosis in HeLa cells It is acknowledged that high-risk HPV-18 E6 protein has an important role in the regulation of p53 degradation in HPV-positive HeLa cells. To elucidate the cross-talk between E6 and p53, we first attempted to verify the association between p53 and HPV-18 E6 expression, if any, in celecoxib-treated HeLa. The existence of E6-p53 cross-talk was also verified in a battery of HPV-DNA-negative cancer cells, which were ectopically allowed to express HPV-18 E6 oncogene. For this purpose, wild-type p53 expressing and HPV-18 E6 negative cancer cells, for example, MCF-7, HBL-100, A549 and H460 were transfected with HPV-18 E6-complementary (c)DNA (Figure 2a) . After 24 h of treatment/transfection, p53 and E6 protein expression levels were checked by immunoblotting with anti-p53 and anti-E6 antibodies, respectively. The data clearly indicate that p53 expression correlated inversely with HPV-18 E6 expression (Figure 2a ). It is, therefore, conceivable that downregulation of E6 by celecoxib might have resulted in p53 accumulation in HPV-18-infected cervical cancer cells. In fact reverse transcription (RT)-PCR and western blotting experi- Regulation of pro-and anti-p53 network for cancer apoptosis B Saha et al ments indicated that E6 was significantly downregulated at both mRNA and protein levels by celecoxib in HeLa cells with increasing time points (Figure 2b ). All these results along with the reverse correlation between HPV-18 E6 and p53 expression profiles together indicated that in HPV-positive cervical cancers, celecoxib induced p53 accumulation by repressing E6 expression. To further verify our hypothesis, next we checked the status of ubiquitinated p53 in celecoxib-treated cells. Results of Figure 2c revealed that although there was significant p53 ubiquitination in control HeLa cells, celecoxib treatment resisted the same and stabilized p53 in a timedependent manner. Involvement of E6 in p53 degradation was next reconfirmed by transfecting HeLa cells with E6-siRNA ( Figure 2c ). As E6 and E7 genes are expressed together as polycistronic transcripts from a common promoter, it was necessary to construct E6specific siRNA and verify the specificity of E6-siRNA. Thus, to specifically block E6 expression, siRNA to E6 was designed against the 19-nt intronic sequence present only in E6 transcript (Butz et al., 2003) . Specificity of the E6-siRNA was verified by analyzing the status of E6 and E7 and by monitoring E6-/E7-regulated downstream genes p53 and cyclin A. We observed that E6-siRNA exclusively inhibited E6 without effecting E7 expression (Figure 2c ). Moreover, silencing E6 restored p53 but failed to alter cyclin A levels ( Figure 2c ). On the other hand, cells transfected with E7-siRNA manifested reduced levels of both E6 and E7 (Figure 2c ). Consistently, these cells also exhibited upregulation of p53 and downregulation of cyclin A expression (Figure 2c ). These results strongly reiterated the specificity of E6-siRNA and made it appropriately useful for further experiments. As observed with celecoxib treatment, as p53 was also accumulated in E6-silenced cells (Figure 2c ), it appeared Inverse relationship between E6 and p53 was further reconfirmed in wild-type p53-expressing and HPV-18 E6-negative/-positive cancer cells, for example, MCF-7, HBL-100, A549 and H460 cells transfected with/without E6-cDNA. HPV-18 E6-negative cancer cells were transiently transfected with pcDNA3.1 (control vector) or pcDNA3.1-encoded E6 (E6-cDNA) for 24 h and assayed for E6 expression by western blot. E6 overexpression was associated with decrease in the levels of p53 in HPV-negative cancer cells. (b) Time-dependent variation in the expression profiles of E6 at mRNA and protein levels were determined by RT-PCR and western blotting in celecoxibtreated in HeLa cells. (c) After celecoxib treatment for the indicated time, p53 was immunoprecipitated from HeLa cell lysates with anti-p53 antibody and immunoblotted with anti-Ub antibody to assay p53 ubiquitination. The ladder of bands represented ubiquitinated p53 which decreased with 24 h of celecoxib exposure. The immunoprecipitates were further assayed for p53 expression by western blot. Comparable protein input was determined by direct western blotting with anti-a-actin using 20% of the cell lysates that were used for immunoprecipitation. Lysates from untreated and celecoxib-treated cells were also subjected to immunoprecipitations with control IgG and the subsequent immunoprecipitates were blotted with anti-p53 antibody. HeLa cells were transiently transfected with a non-targeting control siRNA or E6-/E7-siRNA. Transfection specificity was next evaluated by RT-PCR and western blot analysis of E6/E7 in cells transfected with siRNAs. Western blot analysis of p53, cyclin A in E6/E7-siRNA transfected cells further evaluated the specificity of E6-/E7-siRNA. (d) p53 expression in nuclear and cytosolic fractions of untransfected/E6-siRNA-transfected HeLa cells treated with ± celecoxib for 24 h was determined by western blot analysis. In a parallel set of experiment, total RNA was subjected to RT-PCR analyses to determine the mRNA profile of p53, Bax and PUMA. Percent apoptosis was scored with Annexin-V-FITC/propidium iodide flowcytometric assay in untransfected/E6-siRNA/E6-cDNA-transfected HeLa cells treated with ± celecoxib and were represented graphically. Transfection specificity of E6-cDNA-transfection was evaluated by western blot analysis (inset; right panel). The a-actin, histone H1 and GAPDH were used as loading control. Values are mean±s.e.m. of five independent experiments in each case or representative of typical experiment.
that abrogation of E6 is imperative for p53 accumulation and celecoxib is protecting p53 from degradation by downregulating E6.
Next we explored whether downregulation of E6 is sufficient to restore p53 function in HPV-18-infected Hela cells. In E6-siRNA-transfected HeLa cells, although p53 level increased in a time-dependent manner (Figure 2c ), translocation of p53 to nucleus, the pre-requisite for p53 function, remained unchanged as compared with celecoxib-treated cells (Figure 2d ). Supporting these results, silencing of E6 could neither induce the expression of p53-transactivated proteins, Bax and PUMA nor produce apoptosis when compared with celecoxib treatment in HeLa cells (Figure 2d ). Interestingly, previous results have already demonstrated that treatment of celecoxib not only resisted p53 degradation but also potentiated p53 translocation to nucleus and increased Bax and PUMA levels in HeLa cells ( Figure 1d ). Even though E6 silencing alone failed to induce p53 function, that E6 downregulation was indeed inevitable for celecoxib-mediated apoptosis was further confirmed when transfecting Hela cells with E6-cDNA significantly, though not completely, decreased the anti-cancer effects of celecoxib ( Figure 2d ). Although the earlier reports have shown that viral E6 is the predominant p53 antagonist in cervical cancer cells, (Butz et al., 2000 (Butz et al., , 2003 Saito et al., 2003; Horner et al., 2004; Hengstermann et al., 2005; Perfettini et al., 2005) our results indicated that downmodulation of E6 alone, though important, is not sufficient for functional restoration of p53. All these findings point towards the possibility of the involvement of other factor(s) in celecoxib-induced functional restoration of p53 and HeLa cell apoptosis.
Celecoxib restores p53 transcription and abrogates cytoplasmic sequestration of p53 by downregulating Cox-2 We then sought to identify the key factors, besides HPV-18 E6 oncogene, of celecoxib-mediated p53-dependent cervical cancer cell apoptosis. As celecoxib is known to abate not only Cox-2 activity (Reddy et al., 2000) but also its expression (Narayanan et al., 2006) , we asked the question whether downmodulation of Cox-2 is having any role in restoring p53 function in HPVinfected cervical cancer cells. Our results depict that celecoxib could successfully inhibit both Cox-2 expression and its activity in HeLa cells (Figure 3a) . Based on earlier studies where E6/E7 upregulated Cox-2 in HPV-16 cervical cancer cells (Subbaramaiah and Dannenberg, 2007) , we hypothesized that E6 downregulation, as observed in our results, had a crucial role in Cox-2 inhibition during celecoxib-mediated apoptosis. However our results showed that E6 knockdown did not significantly alter Cox-2 levels ( Figure 3a) indicating that celecoxib-dependent Cox-2 inhibition was E6 independent. Previous reports have shown that Cox-2 and p53 negatively regulate each other with their interactions being physiologically relevant (Han et al., 2002; Corcoran et al., 2005; de Moraes et al., 2007) . Consistently, silencing Cox-2 restored p53 transcript with negligible change in p53 protein in Hela cells (Figure 3b ). This is in agreement with our previous results where HeLa cells with intact E6 manifest minimal p53 protein expression (Figure 2a ). However celecoxib-treated cells exhibited profound restoration of p53 transcript when compared with Cox-2-siRNA-transfected cells. This suggested the involvement of molecules/pathways other than Cox-2 during celecoxib-mediated upregulation of p53 transcription. Apart from inhibiting p53 transcription, Cox-2 is also known to negatively regulate p53 function (Corcoran et al., 2005) . To verify this further, we next selected MCF-7 cells and E6-siRNA-transfected HeLa cells to understand the interaction between Cox-2 and p53. In these cells, p53 co-precipitated with Cox-2, (Figure 3c ) thereby reconfirming their direct physical interaction. However, such physical interaction was significantly inhibited upon celecoxib treatment due to reduced Cox-2 levels and more p53 was available to the nucleus of these cells (Figure 3c) . Consistently, overexpression of Cox-2 in HeLa cells significantly decreased celecoxib-induced apoptosis, thereby suggesting that Cox-2 indeed was responsible for quenching both p53 transcription and function (Figure 3e ).
In that case abrogating both Cox-2 and E6 seems to be crucial for finally upregulating p53 at translational level. All these results together indicate that celecoxib on one hand reduced Cox-2 level thereby augmenting p53 transcription and on the other hand negated the association between Cox-2 and p53 protein thereby liberating p53, which was further stabilized by E6 downregulation. As a result, p53 became available for translocation to the nucleus for expression of p53-transactivated genes, for example, Bax and PUMA (Figure 3d ). Interestingly, in contrast to celecoxib, HeLa cells transfected with siRNAs of E6 and Cox-2, either alone or in combination (Figure 3e ; inset), could neither upregulate Bax or PUMA, nor could undergo apoptosis (Figures 3d and e) , thereby indicating that suppressing the anti-p53 network involving E6 and Cox-2 is also not sufficient to execute p53 transcriptional functions. These results raise the possibility of involvement of other factor(s)/phenomenon in functional activation of restored p53.
Celecoxib activates p53 via ATM and p38MAPK by phosphorylating it at serine-15 and -46, respectively It is known that to circumvent diverse activities in response to varied stress stimuli, p53 protein is under tight regulatory control of post translational modifications where phosphorylation is one of the key events modulating p53 functions (Appella and Anderson, 2001; Saito et al., 2003) . Our search for the factors responsible for functional activation of restored p53 divulged that in response to celecoxib, p53 manifested phophorylation at serine-15 and -46 residues with serine-15 being induced in early hours followed by serine-46 phopshorylation (Figure 4a ). Consistent with E6 knockdown failing to achieve p53 nuclear translocation and transactivation of p53-dependent genes in HeLa cells at 24 h (Figure 2d ), lack of phophorylation at serine-15 and -46 residues of p53 in E6-silenced cells (Figure 4a ) further assured that celecoxib induced p53 post-translational modifications independent of E6.
Next based on earlier studies (Perfettini et al., 2005) where p38 mitogen-activated protein kinase (p38MAPK) regulated p53 functions in response Figure 3 Celecoxib downregulates Cox-2 to increase p53 transcript and to relieve p53 from cytoplasmic sequestration. (a) Hela cells were exposed to celecoxib (25 mM) for various time points and then were examined for Cox-2 expression at both protein and mRNA levels by western blotting and RT-PCR, as well as subjected to enzyme-linked immunosorbent assay for determining Cox-2 activity. In parallel, these cells were transiently transfected with control-siRNA and E6-/E7-siRNA and assayed for Cox-2 expression by western blot. (b) HeLa cells were transiently transfected with control-siRNA and Cox-2-siRNA and assayed for p53 expression by RT-PCR and western blot analysis. (c) Simultaneously, co-immunoprecipitation experiment was employed to study the physical interaction of Cox-2 and p53 in MCF-7 and E6-silenced HeLa cells in the presence or absence of celecoxib. Approximately 300 mg of protein from celecoxib-treated MCF-7 and E6-silenced HeLa cells was subjected to immunoprecipitation using anti-p53/anti-Cox-2 antibody or with control IgG. The same blot was sequentially probed with Cox-2 and p53-specific antibodies. To confirm comparable protein input of the respective samples following, 20% of lysates used for immunoprecipitation were subjected to western blot analysis with anti-aactin. In parallel, celecoxib-induced nuclear translocation of p53 was determined in nuclear lysates of MCF-7 and E6-silenced HeLa cells by western blot analysis. (d) p53 nuclear translocation in E6-and/or Cox-2-siRNA transfected HeLa cells incubated with±celecoxib were determine by western blot analysis and activation of its downstream targets, Bax and PUMA were assayed by RT-PCR. (e) In parallel experiment, percent apoptosis was scored by Annexin-V/propidium iodide-positivity in untransfected/Cox-2-siRNA/Cox-2-cDNA/E6-siRNA HeLa cells. HeLa cells were transfected with Cox-2-cDNA/Cox-2-siRNA/E6-siRNA or control empty vector or control-siRNA and scored for transfection efficiency was assayed by evaluating the expression of Cox-2 and E6 by western blotting (insert). a-actin, histone H1 and GAPDH were used as loading control. Values are mean ± s.e.m. of five independent experiments in each case or representative of typical experiment.
Regulation of pro-and anti-p53 network for cancer apoptosis B Saha et al to celecoxib-induced DNA damage, we attempted to evaluate the role, if any, of p38MAPK in celecoxib-induced p53 activation. Our results indicated time-dependent upregulation and phosphorylation of p38MAPK in HeLa cells up on celecoxib treatment (Figure 4a ). To further clarify a mechanistic link between celecoxib, p38MAPK and p53 phosphorylation we undertook two approaches, that is, celecoxibinduced p53 phosphorylation was assessed in HeLa cells (a) exposed to SB203580, a pharmacological inhibitor of p38MAPK, and (b) transfected with p38MAPK-siRNA. Results of Figure 4b demonstrated that both the approaches abolished phosphorylation of p53 at serine-46 along with p38MAPK phosphorylation without altering total p53 and E6 levels. This was also accompanied with inhibition of Bax and PUMA transactivation and significantly reduced HeLa cell apoptosis (Figure 4b ). However, both these conditions failed to affect serine-15 phosphorylation of p53 in these celecoxib-treated cells (Figure 4b -phosphorylation during celecoxib treatment, HeLa cells were subjected to ATM-siRNA transfection and ATM kinase inhibitor Wortmannin treatment in two different set of experiments. Interestingly, gene silencing and pharmacological inhibition approaches apart from decreasing levels of phosphorylated ATM also abrogated p53 phosphorylation not only at serine-15 residues but also at serine-46 residue although phospho-p38MAPK, p53 and E6 levels remained unaffected (Figure 4d ). Inhibition of ATM thereby remarkably blocked celecoxib-mediated apoptosis (Figure 4d ). All these results together underscore the role of both ATM and p38MAPK as pro-apoptotic kinases in sustaining transcriptional functions of p53 during celecoxib-mediated apoptosis where ATMmediated serine-15 phosphorylation of p53 could have prepared the environment in favor of p-p38MAPK-induced p53 phosphorylation at serine-46 residue for subsequent transactivation of Bax and PUMA. As Moody and Laimins (2009) described that E7-ATM association is an essential factor for viral genome replication in HPV31-infected differentiated keratino- Regulation of pro-and anti-p53 network for cancer apoptosis B Saha et al cytes by arresting the cell at G2/M phase, it became necessary to evaluate the role of E7 in regulating ATMdependent p53 activation in HPV-18 positive HeLa cells. However, in our system, E6 knockdown that spared E7, restored p53 (Figure 2c ) but failed to induce p53 phosphorylation (Figure 4a ) and apoptosis (Figure 2d ) within 24 h thereby indicating that E7-ATM association, if any, did not have any significant role in HeLa cell apoptosis at this time point.
Effects of celecoxib in different grades of HPV-infected human cervical carcinoma tissues Studies performed in in vitro system were confirmed by reiterating in primary cervical carcinoma tissue samples obtained from surgical biopsies with prior consent of patients. Five samples of each, cervical intraepithelial neoplasia-intermediate stage (CIN II and CIN III) , cervical squamous cell carcinoma-full blown cancer samples and normal cervical epithelial cells (control) were tested. The biopsy samples procured were initially tested for HPV positivity and HPV-18-positive samples were digested to obtain single cells, which were again screened for HPV-18 positivity by RT-PCR. Only HPV-18 positive cells were finally selected for the experiments. Our results demonstrated that celecoxib induced B50% cell death in CIN II, CIN III and cervical squamous cell carcinoma, compared with 8% death in normal cervical cells (Figure 5a ). We also verified the status of E6 oncogene, Cox-2 and p53 in each of the samples by western blot analysis. Experimental findings revealed that celecoxib decreased E6 and Cox-2 proteins with simultaneous increase in p53 protein (Figure 5b ). Our results thus support the role of celecoxib in mediating p53-induced apoptosis in HPV-18-infected cervical cancer.
Discussion
p53 with its ideal 'guardian angel and anti-tumor prototype' continues to fascinate scientists and clinicians all over the world. Novel findings adding to the complexity of tumor preventive properties of p53 every year implicate p53 in an ever growing number of clinically safe practices (Sigal and Rotter, 2000; Ishida et al., 2003) . However, inactivation of p53 in cancer is very common and usually occurs by mutation, deletion or through inhibitory binding with viral oncoproteins (Sigal and Rotter, 2000; Vogelstein et al., 2000; Ishida et al., 2003) . Although in cases where p53 is not inactivated by classical mechanisms, alternate components of its network have been targeted (Kuperwasser et al., 2000) . Apart from this, p53 may also be targeted by oncogenic proteins in many malignant and premalignant tissues involving its abnormal sequestration in the cytoplasm where it is functionally muted or turned off (Jeong et al., 2005) . Though 'p53 in action' concept may appear simple and exciting, for the action to become realistically functional it requires p53 to undergo a series of molecular remodeling processes and simultaneously overcome the negative pressures from the anti-p53 setting. During this tour of functional maturation, cellular network acts together to target p53 at transcriptional, translational and post-translational levels (Zhao and Liao, 2003) . Therefore, anti-cancer therapies should aspire to globally activate or restore p53 functions not only by targeting anti-p53 network but also by triggering pro-p53 settings.
Our study deals with the pharmacological restoration of transcriptionally active p53 in HPV-18-infected cervical cancer cells, which, regardless of possessing wild-type gene, fail to manifest functional p53. In-depth Regulation of pro-and anti-p53 network for cancer apoptosis B Saha et al exploration of underlying mechanism revealed that celecoxib adopts three different mechanisms to achieve full-fledged execution of p53-mediated cancer cell killing, which includes (i) upregulation and stabilization of p53, (ii) inhibition of cytoplasmic sequestration of p53 and (iii) triggering of p53 transcriptional functions. Our results portrayed an inverse correlation between Cox-2 and p53 where celecoxib, by inhibiting Cox-2, restored p53 transcription and function in HeLa cells. This is in harmony with studies describing that endogenous Cox-2 physically interacts with p53 and negatively affects p53-dependent transcriptional activity (Corcoran et al., 2005) and inhibition of Cox-2 leads to increase in p53-dependent apoptosis (Han et al., 2002) . However, enhanced p53 transcription in Cox-2-silenced HeLa cells failed to accumulate sufficient p53 suggesting celecoxib globally overpowered other anti-p53 settings. Cancer cells are often characterized by a deregulated p53 system due to hyper-activation of p53-degrading machinery (Espinosa and Emerson, 2001; Wang et al., 2003) . Under physiological conditions, p53 is expressed at low or undetectable levels with a half life of 10-20 min in most cells (Espinosa and Emerson, 2001 ). The ubiquitinproteosome pathway following the interaction of murine double minute 2 with the amino terminus of p53, at least in part, mediates this rapid degradation (Wang et al., 2003) . However, in case of HPV-infected cervical cancer cells, murine double minute 2 is not significantly detectable and is functionally replaced by viral oncoprotein E6 (Scheffner et al., 1993) . This is the first report ever demonstrating that celecoxib, by downregulating E6 both at transcriptional and translational levels, protects p53 from degradation in HPV-18-infected cervical cancer cells. Though Subbaramiah and Dannenberg (2007) have observed that E6/E7 can upregulate Cox-2 expression levels, celecoxib-mediated Cox-2 downregulation as observed in our system was independent of E6/E7. A closer look into studies by this group revealed that E6/E7-mediated Cox-2 upregulation was a result of amphiregulin binding but not EGF binding to EGFR. In another study (Yasumoto et al., 1991) , EGF, by activating the silencer activity of EGF responsive element in the LCR region of HPV-16 genome, elicited negative regulation of E6/E7 at the mRNA level in immortalized human keratinocyte. From the above studies by these two groups it can be predicted that as EGF negatively regulates E6/E7, HPV-16-E6/E7 to rescue themselves might have evolved with amphiregulin as a substitute for EGF. The amphiregulin upon binding to EGFR though induced Cox-2 as expected downstream of EGFR signaling, it did not induce the silencing activity of EGF responsive element as Subbaramiah and Dannenberg (2007) did not observe reduced E6/E7 transcription due to amphiregulin-mediated EGFR-signaling. Thus amphiregulinmediated Cox-2 upregulation by HPV-16 E6/E7 appears not to be a general mechanism but a way out for overcoming the negative influence of EGF on HPV-16 E6/E7, a mechanism specific for HPV-16-infected cells due to the mere presence of EGF-responsive silencer in the HPV-16 LCR. Based on the differences of LCR in HPV-16/HPV-18 (Romanczuk et al., 1991) and the fact that EGF regulates Cox-2 in different cells (Mestre et al., 1997; Sato et al., 1997; Molina et al., 1999) , it can be predicted that in HeLa cells that harbor HPV-18 virus, Cox-2 regulation might be independent of E6/E7-amphiregulin signaling. This notion is supported by the reports that nitric oxide induces Cox-2 expression in Hela cells and EGFR phosphorylation (Lee et al., 2008) , thereby suggesting that Cox-2 regulation in HPV-18 is independent of E6/E7-amphiregulin-signaling. Also due to the higher aggressiveness of HPV-18 over HPV-16, it can also be predicted that the predominant silencer activity of EGF responsive element involved in HPV-16 E6/E7 downregulation might be restricted to HPV-16, though a detail gene sequence analysis of EGF responsive elements of both HPV-16 and HPV-18 might further answer this issue. Scheffner et al. (1993) have provided direct evidence for the active role of E6-binding aptamers in abrogating p53 degradation in HPV-16-positive cells. As p53 has a crucial role in safeguarding the integrity of the genome, cells expressing HPV E6 show chromosomal instability, which greatly increases the probability that HPVinfected cells will evolve towards malignancy (Malanchi et al., 2002) . Therefore, functional activation of p53 by targeting E6 represents a key step in regressing cervical carcinogenesis. Several studies have demonstrated that functional perturbation of viral oncogenes results in senescence or apoptosis in cervical cancer cells (Butz et al., 2000 (Butz et al., , 2003 Horner et al., 2004; Hengstermann et al., 2005) . Genetically silencing E6 with pSUPER-18E6 (Butz et al., 2003) or peptide aptamers (Butz et al., 2000) remarkably restores functional p53 and induces apoptosis in cervical cancer cells at day 3-4 (Butz et al., 2000 (Butz et al., , 2003 or 1 week (Horner et al., 2004) . In our study, although celecoxib was proficient to induce apoptosis in HPV-18 infected cervical cancer cells within 24 h of its exposure, silencing E6 during early hours failed to furnish any such effects. However with time, that is, after day 3, E6 knockdown produced significant apoptosis with simultaneous nuclear translocation of p53 and transactivation of p53-dependent genes Bax and PUMA (Supplementary 1A-C) .
Interestingly, our results demonstrate that loss of E6 alone, though stabilized p53, failed to induce p53 nuclear localization and p53-dependent transcriptional functions at 24 h suggesting that celecoxib targets other regulators of the anti-p53 network. Despite the wildtype p53 status, cancer cells are often characterized by cytoplasmic sequestration of p53 (El-Deiry, 2003) . In mammals, reversal of cytoplasmic sequestration of p53 can be achieved by a variety of means all of which result in translocation of p53 to the nucleus (Becker et al., 2007) . Their renewed presence in the nucleus allows direct p53-related transcriptional activities, usually resulting in apoptosis of the cancer cells. In all cases so far observed, reversal of cytoplasmic sequestration and resultant nuclear function of p53 protein requires either a reduction in the amount or availability of the cytoplasmic anchoring protein or in DNA damagedependent overproduction and activation of p53 family proteins (Walker et al., 2006) . In this regard, Cox-2 in earlier studies has been primarily regarded to influence p53 in a rather negative manner (Swamy et al., 2003; Corcoran et al., 2005; de Moraes et al., 2007) . Moreover, targeting Cox-2 seems rational not just to improve p53 functions but because most virally infected cervical cancers are a result of Cox-2-dependent inflammatory reactions (Ryu et al., 2000; Subbaramaiah and Dannenberg, 2007) . Here, we show that celecoxib impedes Cox-2 expression, which not only upregulates p53 transcription but also overrides Cox-2/p53 association to facilitate nuclear localization of p53. Reduced binding between Cox-2 and p53 as a result of decreased Cox-2 expression upon celecoxib treatment rescues p53 from Cox-2-dependent sequestration. This effect enhances the responsiveness of p53 to DNA damage, suggesting that celecoxib sensitizes cells to p53-responsive stresses by promoting p53 localization in the nucleus and enabling its activity as a transcription factor for pro-apoptotic genes Bax and PUMA. This finding is in harmony with studies by Swamy et al. (2003) who describe that celecoxib protects p53 activity by inhibiting Cox-2 in colon cancer cells. Overcoming the negative influences of cytoplasmic sequesters would therefore amplify the functional impact of p53-dependent death circuit. As high levels of Cox-2 expression in cervical cancers has been well correlated with tumor cell proliferation, reduced apoptosis and induction of angiogenesis thereby exhibiting a more aggressive phenotype and a lower response to standard therapy with shorter survival times (Ryu et al., 2000; Munkarah and Ali-Fehmi, 2005) , improvement of p53 function via downregulation of Cox-2 by celecoxib raises the possibility of the development of a targeted therapy of HPV-18-infected cervical cancers.
However, as inhibition of E6 and Cox-2 failed to induce functional activation of p53, it appeared that celecoxib might be targeting other members of the antior pro-p53 networks during cervical cancer apoptosis. Multiple post-translational modifications of p53 involving ubiquitinylation, phophorylation, acetylation are important determinants of p53 with regards to its stability, sub-cellular localization and transcriptional functions. Among these phosphorylations at specific serine and/or threonine residues are the most common modifications of p53 (Blagosklonny, 2000; Appella and Anderson, 2001; Saito et al., 2003; Perfettini et al., 2005) . Under condition of cellular stress, p53 is highly phosphorylated by a number of specific protein kinases including ATM, ATR, CHK2, DNA-PK, HIPK2 and MAPKs (Blagosklonny, 2000; Appella and Anderson, 2001; Saito et al., 2003; Perfettini et al., 2005) . However, none of the pathways can induce all the phosphorylation pathways and the phosphorylation of p53 is different in response to different stimuli (Blagosklonny, 2000) . Celecoxib in the present study induced p53 serine-15 and serine-46 phosphorylations. DNA damage signals are known to induce phosphorylation of serine-15 culminating in increased stability and nuclear localization of p53 (Frank et al., 2006; Amano et al., 2009) . On the other hand, phospho-serine-46 is required for transcriptional regulation of many p53-dependent genes involved in cell cycle arrest and apoptosis (Ichwan et al., 2006) . Interestingly, phosphorylation at serine-15 in some cases is a prerequisite for different protein kinases to induce transcriptionally active p53 (Ichwan et al., 2006) . As observed in our study, celecoxib-activated ATM, blocking which significantly abrogated apoptosis and p53 phosphorylation at both serine-15 and serine-46, sparing p38MAPK which still remained active. In contrast, inhibiting p38MAPK though restrained phosphorylation of p53 at serine-46 as well as Bax and PUMA transactivation and apoptosis, serine-15 phopshorylation remained unaffected. These results suggest that in celecoxib-treated cervical cancer cells, activation of ATM in response to DNA damage phosphorylates p53 at serine-15, which then facilitates p38MAPK-dependent p53 phosphorylation at serine-46 to finally result in functional restoration of this tumor suppressor. Consistently Kang et al. (2009) reported that celecoxib-induced DNA damage, accompanied inhibition of DNA synthesis and p53-dependent Figure 6 Schematic illustration depicting differential regulation of anti-and pro-p53 network in HPV-18-infected cervical cancer cell by celecoxib.
Regulation of pro-and anti-p53 network for cancer apoptosis B Saha et al autophagy events in U87MG cells. Another study proposes induction of DNA damage by the Cox-2 inhibitor R-flurbiprofen following the observation that R-flurbiprofen increases p-Ser 15 -p53 phosphorylation in colon cancer cells (Gro¨sch et al., 2005) . Based on the above literature it can be said that DNA damage following celecoxib treatment might have contributed to ATM and p38MAPK activation and hence induction of transcriptionally active p53. However, the mechanisms underlying celecoxib-induced DNA damage remain unclear and are beyond the scope of this study.
Finally the anti-cancer effects of celecoxib were reinstated in HPV-18-infected cervical tumors of different grades. Our findings of celecoxib-induced cervical cancer apoptosis are further clinically relevant as low concentration of celecoxib is attainable in human serum (Kang et al., 2009) .
In summary our study highlights that suppressing the anti-p53 networks including E6 and Cox-2 while promoting the pro-p53 networks like ATM/p38MAPK signaling by celecoxib may serve as an important regulator of functional restoration of p53 in virally infected cervical cancers ( Figure 6 ). Therefore, the discovery of yet unidentified mechanisms that differentially maneuver anti-and pro-p53 network raises new hopes for more efficient cancer therapy in the not so distant future.
Materials and methods

Cell culture and treatments
The cervical cancer cell line HeLa (p53 degraded/HPV-E6 positive), breast cancer cell line-MCF-7 and HBL-100 (p53 wild-type/HPV-E6-negative), lung cancer cell line-A549 and H460 (p53 wild-type/HPV-E6-negative), MRC-5 (human lung fibroblast cells) were obtained from National Centre for Cell Science, Pune, India. The cells were routinely maintained in complete Dulbecco's modified Eagle's medium or RPMI 1640 medium at 37 1C in a humidified incubator containing 5% CO 2 . Cells were allowed to reach confluence before use. Viable cell numbers were determined by Trypan blue exclusion test. Peripheral blood collected from healthy human volunteers with informed consent was centrifuged over Ficoll-Hypaque density gradient (Amersham Pharmacia, Uppsala, Sweden) to obtain total leukocytes. Cells were treated with different concentrations of celecoxib (Sigma, St Louis, MO, USA) for different time points to select the optimum dose and time required for cancer cell apoptosis. An equivalent amount of carrier (dimethyl sulfoxide) was added to untreated cells. To evaluate the involvement of p38MAPK and ATM in celecoxibinduced apoptosis, HeLa cells were pretreated with specific p38MAPK inhibitor (SB203580, Sigma; 10 mM, Calbiochem, Gibbstown, NJ, USA) 90 min before treatment and with specific ATM inhibitor (Wortmanin; 20 mM, Calbiochem) 30 min before celecoxib treatment.
Determination of Cox-2 activity Cox-2 activity was determined by enzyme-linked immunosorbent assay using kits from Cayman Chemicals (Ann Arbor, MI, USA) following the manufacturer's instruction. Each measurement was repeated in triplicate, and the mean value was recorded as U/ml.
Isolation and culture of primary cervical cancer cells Primary lesions of cervical cancer and normal cervical tissue were obtained from SSKM Hospital, Kolkata, India. Informed consent was obtained from all patients with localized disease. These tumors were exclusively primary site cancers that had not been treated with either chemotherapy or radiation. The histopathologic diagnosis was based on the criteria of the International Federation of Gynecology and Obstetrics and the World Health Organization of uterine cervical lesions. The selected cases consisted of five cases each of CIN-intermediate stage (CIN-II and III), cervical squamous cell carcinoma and normal cervical epithelium. Normal cervical tissue was collected from removed uteri without malignancy, which served as a control. The specimens were washed with phosphate buffered saline, cut into small pieces, 5 Â 5 mm in size, and immersed in 0.125% trypsin-EDTA at 4 1C overnight. Then the specimens were gently dissected with forceps into single cells, seeded on poly-L-lysine coated dishes and cultured for 1 day at 37 1C in a serum-free medium, KGM containing 0.1 ng/ml human recombinant epidermal growth factor, 5 mg/ml insulin, 0.5 mg/ml hydrocortisone, 50 mg/ml gentamycin, 50 ng/ml amphotericin-B and 15 mg/ml bovine pituitary extract. Medium was replaced every 4 days and passages were done when the cells reached, 80% confluence (Kawamata et al., 2002) .
Detection of HPV infection in biopsy sample
The biopsy samples procured were initially tested for HPV positivity and HPV-18 positive samples were digested to obtain single cells, which were then further screened for HPV-18 positivity. Genomic DNA was extracted from paraffinembedded specimens or single cells using tissue DNA extraction kit (Prince et al., 2007) . HPV detection was performed using the consensus primers GP5 þ /GP6 þ from the L1 region of the HPV genome. PCR-positive cases were further characterized using PCR with HPV 16-specific primers (URR; forward 5 0 -GCAGCTCTGTGCATAAC-3 0 , reverse 5 0 -CTGCACATGGGTGTG TGC-3 0 ) as well as HPV 18-specific primers (E2-gene; forward 5 0 -GAATTCACTCTATG TGCAG-3 0 , reverse 5 0 -TAGTTGTTGCCTGTAGGTG-3 0 ). Identification of PCR products was done in a 10% polyacryamide gel with silver nitrate staining. The integrity of the extracted DNA was tested by amplifying a fragment of the human GAPDH gene. Appropriate positive, negative, and contamination controls were included in the PCR assays to verify the specificity of the method. Only HPV-18 positive cells were finally selected for the experiments.
Flow cytometry
For the determination of cell death, cells were stained with propidium iodide and Annexin-V-FITC (BD Pharmingen, San Diego, CA, USA) and analyzed on flow cytometer (FACS Calibur, Beckton Dickinson, Mount View, CA, USA). Electronic compensation of the instrument was done to exclude overlapping of the emission spectra. Total 10 000 events were acquired for analysis using CellQuest software (Beckton Dickinson). Annexin-V/propidium iodide-positive cells were regarded as apoptotic cells (Das et al., 2008a, b) .
Immunoblotting and co-immunoprecipitation Cells were lysed in buffer (10 mM Hepes, pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl and 0.5 mM dithiothreitol) and spun at 3300 g to get cytosolic fraction. Pellet was resuspended in buffer (20 mM Hepes, pH 7.9, 0.4 M NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA and 0.5 mM dithiothreitol) and spun down at 12 000 g for 30 min to get nuclear fraction. For whole cell lysates, cells were resuspended and homogenized in buffer (100 mM Tris-Cl, pH 7.4, 300 mM NaCl, 1% NP-40 and 0.25% sodium-deoxycholate). All the buffers were supplemented with protease and phosphatase inhibitor mixtures (Bhattacharyya et al., 2007; Lahiry et al., 2010) . For direct western blot analysis, the cell lysates or the particular fractions were separated by SDSpolyacrylamide gel electrophoresis, transferred to nitrocellulose membrane and probed with specific antibodies, for example, anti-p53, -p63, -p73, -E6, -E7, -p21, -Bax, -PUMA, -ATM, -p-p38MAPK, -p38MAPK, -p-Ser-15-p53, -p-Ser-46-p53, -Cox-2, -Ub, -caspase-3, produced from Santa Cruz (Santa Cruz, CA, USA), thereafter the immunoblots were visualized by chemiluminescence. Equal protein loading was confirmed with a-actin/ Histone-H1/MnSOD antibody (Santa Cruz). For the determination of direct interaction between two proteins, co-immunoprecipitation technique was employed (Bhattacharyya et al., 2007; Lahiry et al., 2010) . Cox-2 and p53 reciprocal co-IP and p53-ubiquitin interaction were performed using cell lysates prepared in Nonidet P-40 (1%) lysis buffer containing protease inhibitors. Samples (300 mg of protein from the total lysate) were incubated at 4 1C overnight with anti-Cox-2 or anti-p53 antibody and then incubated for 2 h at 4 1C with protein G-Sepharose. Immunocomplexes were washed of unbound proteins with cold Tris-buffered saline with protease inhibitors and pelleted beads were boiled for 5 min in SDSpolyacrylamide gel electrophoresis sample buffer. The immunoprecipitated proteins were resolved on SDS-polyacrylamide gel electrophoresis and analyzed by western blotting for detection of p53/Cox-2 or Ub. The input protein used in immunoprecipitation was confirmed by western blotting with anti-a-actin.
RT-PCR assay
Two mg of the total RNA, extracted from cells with TRIzol reagent (Invitrogen, Carlsbad, Carlsbard, CA, USA) was reverse transcribed and then subjected to PCR with enzymes and reagents of the RTplusPCR system (Eppendorf, Hamburg, Germany) using GeneAmpPCR 2720 (Applied Biosystems; Foster City, CA, USA). The cDNAs were amplified with primers specific for HPV-18 E6 (5 0 -AAGCTACCTGATCT GTGCACGG-3 0 /5 0 -GCTGGATTCAACGGTTTC TGG-3 0 ), HPV-18 E7 (5 0 -GGTTGACCTTCTATGTGACGAGCA-3 0 / 5 0 -GTTCAGAAACAGCTGCTGGAAT GC-3 0 ), Bax (5 0 -TT TGCTTCAGGGTTTCATCC-3 0 /5 0 -CAGTTGAAGTTGCC GTCAGA-3 0 ), PUMA (5 0 -CGAC CTCAACGCACAGTAC GA-3 0 /5 0 -AGGCACCTAATTGGGCTCCAT-3 0 ), p53 (5 0 -GG CCCACTTCACCGTA CTAA-3 0 /5 0 -GTGGTTTCAAGGC CAGATGT-3 0 ), Cox-2 (5 0 -TGA TCGAAGACTACGTGCA ACA-3 0 /5 0 -GCG GATGCCAGTGATAGAGTG-3 0 ) and GA PDH (internal control): (5 0 -CA-GAACATCATCCCTGCC TCT-3 0 /5 0 -GCTTGACAAAGTGGTCGTTGAG-3 0 ).
Plasmids, siRNA and transfections
The expression constructs (pcDNA3.0/HA-tagged. 18.E6 (kind gift from Dr David Pim, International Centre for Genetic Engineering and Biotechnology, Padriciano, Trieste, Italy), pcDNA3.1 p53 and pcDNA3.0 Cox-2 and control pcDNA3.0 vectors (2 mg/million cells) were introduced into exponentially growing cancer cells using lipofectamine-2000 (Invitrogen) according to the protocol provided by the manufacturer. Stably expressing clones were isolated by limiting dilution and selection with G418 sulfate (1 mg/ml; Cellgro, Kanas City, MO, USA) and G418 resistant cells were cloned and screened by immunoflourescence and western blotting with specific antibodies. For endogenous silencing of specific genes, cells were transfected with 300 pmol of p53-/HPV-18-/E6-/E7-/Cox-2-/ATM-/p38MAPK-/Bax-siRNA (Santa Cruz) using lipofectamine-2000 separately for 12 h. The mRNA and protein levels were determined by RT-PCR and western blotting.
Fluorescence imaging
For the identification of subcellular localization of p53, celecoxib-treated cells were fixed with 4% p-formaldehyde and permeabilized with Triton X-100. Cells were then stained with anti-p53 antibody followed by Alexa Flour 594-conjugated secondary antibody and visualized with confocal microscope (Carl Zeis, Jena, Germany).
Statistical analyses
Values are shown as s.e.m. Data were analyzed and when appropriate, significance of the differences between mean values was determined by a Student's t-test. Results were considered significant at Po0.05.
Abbreviations
ATM, ataxia telangiectasia mutated; cDNA, complementary DNA; CIN, cervical intraepithelial neoplasia; Cox-2, cycloxygenase-2; HPV, human papillomavirus; MAPK, mitogenactivated protein kinase; PUMA, p53-upregulated modulator of apoptosis; siRNA, short-interfering RNA.
